Ketamine & Emerging Psychedelics: The Solace Behavioral Health Case Study

This;OPEN MINDS;Executive Roundtable was delivered on April 24, 2025 by;Tanveer Chaudhry, M.D., Chief Executive Officer of Solace Behavioral Health (Solace). He discussed the evolving role of ketamine and emerging psychedelics in psychiatric care, with a focus on their transformative potential for treatment-resistant conditions. Drawing from his experiences at Solace, this case study covered how these therapies integrate into clinical practice, their outcomes, and the operational challenges involved.

Executive attendees of this session will:

Understand the clinical and operational benefits of ketamine and emerging psychedelics (including psilocybin and MDMA) for psychiatric care.

Identify . . .